Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

[1]  I. Flinn,et al.  Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study , 2022, Blood.

[2]  M. Konopleva,et al.  S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION , 2022, HemaSphere.

[3]  S. Opat,et al.  Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. , 2022, Blood.

[4]  A. Delmer,et al.  Frontline treatment in CLL: the case for time-limited treatment. , 2021, Hematology. American Society of Hematology. Education Program.

[5]  A. Alencar,et al.  Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia , 2021, Blood.

[6]  D. Rossi,et al.  Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations , 2021, Leukemia.

[7]  Jian-yong Li,et al.  Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday , 2021, Current Medical Science.

[8]  Naveen Garg,et al.  Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations , 2021, Leukemia.

[9]  G. Salles,et al.  Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. , 2019, The Lancet. Haematology.

[10]  A. Alencar,et al.  Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. , 2019, The Lancet. Haematology.

[11]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.